Miraculins Announces Closing of Private Placement Offering

Miraculins Inc. (TSX VENTURE:MOM) (the "Company"), a medical diagnostic company
focused on acquiring, developing and commercializing diagnostic tests and risk
assessment technologies for unmet clinical needs, has closed its recently
announced private placement offering (the "Offering"). The Offering was
over-subscribed with aggregate gross proceeds to the Company of $500,000 from
the sale of 4,545,455 units ("Units") at a price of $0.11 per Unit. Each Unit is
comprised of one common share of the Company (a "Share") and one Share purchase
warrant (a "Warrant"). 


Each whole Warrant entitles the holder to purchase one Share at a price of $0.15
per Share for a period of twelve months from the date the Warrant is issued. The
Shares and Warrants will be restricted from transfer for a period of four months
and a day from the date hereof in accordance with applicable securities laws.
The net proceeds of the Offering shall be used for general corporate purposes. 


Certain persons assisted the Company by introducing potential subscribers for
the Offering and were paid a finder's fee of 8% of the total subscription
proceeds received from subscribers introduced to the Company by each particular
person. Additionally, these persons were issued compensation warrants
("Compensation Warrants") equal to 8% of the total number of Units subscribed
for by subscribers introduced to the Company by each particular person. Each
Compensation Warrant entitles the holder thereof to purchase one Share at a
price of $0.15 per Share for a period of twelve months from the date of issue.
The Compensation Warrants will be restricted from transfer for a period of four
months and a day from the date hereof in accordance with applicable securities
laws.


The closing of the Offering is subject to the final approval of the TSX Venture
Exchange.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
過去株価チャート
から 5 2024 まで 6 2024